Search Results - "Geoffrey I. Shapiro"

Targeting CDK4 and CDK6: From Discovery to Therapy by Sherr, Charles J, Beach, David, Shapiro, Geoffrey I

“…Biochemical and genetic characterization of D-type cyclins, their cyclin D-dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor…”
Get more information

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer by Konstantinopoulos, Panagiotis A, Ceccaldi, Raphael, Shapiro, Geoffrey I, D'Andrea, Alan D

“…Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations…”
Get more information

Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment by SHAPIRO, Geoffrey I

“…Cyclin-dependent kinases (cdks) are critical regulators of cell cycle progression and RNA transcription. A variety of genetic and epigenetic events cause…”
Get full text

Targeting replication stress in cancer therapy by da Costa, Alexandre André B. A., Chowdhury, Dipanjan, Shapiro, Geoffrey I., D’Andrea, Alan D., Konstantinopoulos, Panagiotis A.

“…Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be therapeutically targeted by…”
Get full text

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance by Cornell, Liam, Wander, Seth A., Visal, Tanvi, Wagle, Nikhil, Shapiro, Geoffrey I.

“…CDK4/6 inhibition is now part of the standard armamentarium for patients with estrogen receptor-positive (ER+) breast cancer, so that defining mechanisms of…”
Get full text

Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search by Shapiro, Geoffrey I.

“…In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined…”
Get full text

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration by Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

“…MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs) 1 . These alterations are associated with increased MET activity and…”
Get full text

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F, Li, Yvonne Y, Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D, Nishino, Mizuki, Sholl, Lynette M, Shapiro, Geoffrey I, Awad, Mark M, Cheng, Michael L

“…DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher…”
Get full text

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids by Hill, Sarah J, Decker, Brennan, Roberts, Emma A, Horowitz, Neil S, Muto, Michael G, Worley, Jr, Michael J, Feltmate, Colleen M, Nucci, Marisa R, Swisher, Elizabeth M, Nguyen, Huy, Yang, Chunyu, Morizane, Ryuji, Kochupurakkal, Bose S, Do, Khanh T, Konstantinopoulos, Panagiotis A, Liu, Joyce F, Bonventre, Joseph V, Matulonis, Ursula A, Shapiro, Geoffrey I, Berkowitz, Ross S, Crum, Christopher P, D'Andrea, Alan D

“…Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs…”
Get more information

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma by Morris, John C, Tan, Antoinette R, Olencki, Thomas E, Shapiro, Geoffrey I, Dezube, Bruce J, Reiss, Michael, Hsu, Frank J, Berzofsky, Jay A, Lawrence, Donald P

“…In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human…”
Get full text

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition by Parmar, Kalindi, Kochupurakkal, Bose S, Lazaro, Jean-Bernard, Wang, Zhigang C, Palakurthi, Sangeetha, Kirschmeier, Paul T, Yang, Chunyu, Sambel, Larissa A, Färkkilä, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E, Zou, Lee, Do, Khanh T, Konstantinopoulos, Panagiotis A, Matulonis, Ursula A, Liu, Joyce F, D'Andrea, Alan D, Shapiro, Geoffrey I

“…PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous…”
Get full text

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors by Zhou, Jia, Gelot, Camille, Pantelidou, Constantia, Li, Adam, Yücel, Hatice, Davis, Rachel E, Färkkilä, Anniina, Kochupurakkal, Bose, Syed, Aleem, Shapiro, Geoffrey I, Tainer, John A, Blagg, Brian S J, Ceccaldi, Raphael, D'Andrea, Alan D

“…DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through…”
Get full text

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis by Shaw, Alice T, Dr, Yeap, Beow Y, ScD, Solomon, Benjamin J, MD, Riely, Gregory J, MD, Gainor, Justin, MD, Engelman, Jeffrey A, MD, Shapiro, Geoffrey I, MD, Costa, Daniel B, MD, Ou, Sai-Hong I, MD, Butaney, Mohit, BS, Salgia, Ravi, Prof, Maki, Robert G, MD, Varella-Garcia, Marileila, Prof, Doebele, Robert C, MD, Bang, Yung-Jue, Prof, Kulig, Kimary, PhD, Selaru, Paulina, MSPH, Tang, Yiyun, PhD, Wilner, Keith D, PhD, Kwak, Eunice L, MD, Clark, Jeffrey W, MD, Iafrate, A John, MD, Camidge, D Ross, MD

“…Summary Background ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK…”
Get full text

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer by Plummer, Ruth, Dean, Emma, Arkenau, Hendrik-Tobias, Redfern, Charles, Spira, Alexander I., Melear, Jason M., Chung, Ki Y., Ferrer-Playan, Jordi, Goddemeier, Thomas, Locatelli, Giuseppe, Dong, Jennifer, Fleuranceau-Morel, Patricia, Diaz-Padilla, Ivan, Shapiro, Geoffrey I.

“…•Berzosertib plus gemcitabine was well tolerated in 38 patients with advanced NSCLC.•Preliminary signs of clinical efficacy were observed.•Response rate was…”
Get full text

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors by GANDHI, Leena, CAMIDGE, D. Ross, DIVE, Caroline, ENSCHEDE, Sari H, NOLAN, Cathy, CHIU, Yi-Lin, BUSMAN, Todd, HAO XIONG, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod, SHAPIRO, Geoffrey I, RUDIN, Charles M, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip, GANDARA, David, KHAIRA, Divis, HANN, Christine L, MCKEEGAN, Evelyn M, LITVINOVICH, Elizabeth, HEMKEN, Philip M

“…Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and…”
Get full text

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors by GANDHI, Leena, BAHLEDA, Rastislav, KRYGOWSKI, Mizue, YALI LIANG, TURNBULL, Kathleen W, SHAPIRO, Geoffrey I, SORIA, Jean-Charles, TOLANEY, Sara M, KWAK, Eunice L, CLEARY, James M, PANDYA, Shuchi S, HOLLEBECQUE, Antoine, ABBAS, Richat, ANANTHAKRISHNAN, Revathi, BERKENBLIT, Anna

“…Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members signal via…”
Get full text

Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734 by Morrison-Smith, Chevaun D, Knox, Tatiana M, Filic, Ivona, Soroko, Kara M, Eschle, Benjamin K, Wilkens, Margaret K, Gokhale, Prafulla C, Giles, Francis, Griffin, Andrew, Brown, Bill, Shapiro, Geoffrey I, Zucconi, Beth E, Cole, Philip A, Lemieux, Madeleine E, French, Christopher A

“…NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds…”
Get full text

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance by Johnson, Neil, Johnson, Shawn F., Yao, Wei, Li, Yu-Chen, Choi, Young-Eun, Bernhardy, Andrea J., Wang, Yifan, Capelletti, Marzia, Sarosiek, Kristopher A., Moreau, Lisa A., Chowdhury, Dipanjan, Wickramanayake, Anneka, Harrell, Maria I., Liu, Joyce F., D'Andrea, Alan D., Miron, Alexander, Swisher, Elizabeth M., Shapiro, Geoffrey I.

“…Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP)…”
Get full text

Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection by Cai, Mu-Yan, Dunn, Connor E., Chen, Wenxu, Kochupurakkal, Bose S., Nguyen, Huy, Moreau, Lisa A., Shapiro, Geoffrey I., Parmar, Kalindi, Kozono, David, D’Andrea, Alan D.

“…Cells deficient in ataxia telangiectasia mutated (ATM) are hypersensitive to ionizing radiation and other anti-cancer agents that induce double-strand DNA…”
Get full text

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition by Soucheray, Margaret, Capelletti, Marzia, Pulido, Inés, Kuang, Yanan, Paweletz, Cloud P, Becker, Jeffrey H, Kikuchi, Eiki, Xu, Chunxiao, Patel, Tarun B, Al-Shahrour, Fatima, Carretero, Julián, Wong, Kwok-Kin, Jänne, Pasi A, Shapiro, Geoffrey I, Shimamura, Takeshi

“…Non-small cell lung cancers (NSCLC) that have developed resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), including gefitinib and erlotinib,…”
Get full text